Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kimberly Poarch

Physician Assistant, Medical Dallas, TX Physician Assistant

NPI 1598908337 CMS profile 10630635

10100 N Central Expy, Ste100, Dallas, TX 75231

Open in the dashboard

General payments

$166,180

847 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Poarch of Dallas, TX is reported in the CMS Open Payments database as having received $166,180 across 847 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40,412 217
2024 General $48,095 197
2023 General $26,774 144
2022 General $27,163 139
2021 General $23,735 150

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Poarch
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kimberly Poarch were reported at $40,412. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kimberly Poarch Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $23,735 $156 $41–$563 $132
2022 $27,163 $185 $55–$649 $149
2023 $26,774 $199 $58–$717 $160
2024 $48,095 $206 $62–$740 $164
2025 $40,412 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pharming Healthcare, Inc. $51,962 109 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $39,756 137 payments
  3. CSL Behring $34,608 81 payments
  4. BioCryst US Sales Co., LLC $25,425 109 payments
  5. AstraZeneca Pharmaceuticals LP $2,698 99 payments
  6. Novartis Pharmaceuticals Corporation $2,192 16 payments
  7. Cycle Pharmaceuticals Inc $1,664 8 payments
  8. Regeneron Healthcare Solutions, Inc. $1,590 53 payments
  9. BioCryst Pharmaceuticals, Inc. $1,301 5 payments
  10. Genzyme Corporation $889 37 payments
  11. Other $4,095 193 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $61,212 40 payments
  2. Consulting Fee $46,789 36 payments
  3. Travel and Lodging $21,554 78 payments
  4. Food and Beverage $20,593 676 payments
  5. Honoraria $15,750 11 payments
  6. Education $282 6 payments
Products named General payments · program years 2021–2025
  1. RUCONEST $51,962 109 payments
  2. CINRYZE $23,505 32 payments
  3. Orladeyo $22,704 108 payments
  4. TAKHZYRO $14,116 78 payments
  5. Andembry $11,386 27 payments
  6. Haegarda $8,120 19 payments
  7. FASENRA $1,475 53 payments
  8. DUPIXENT Inflammation And Immunology $1,359 45 payments
  9. DUPIXENT Immunology $1,328 53 payments
  10. NITYR $1,025 1 payment
  11. Other $7,735 340 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

73

Median for Physician Assistant: 241

Drug cost

$2,820,099

Median for Physician Assistant: $4,110

Branded share of claims

100%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Takhzyro Lanadelumab-Flyo Brand 21 $1,037,047
Orladeyo Berotralstat Hydrochloride Brand 22 $963,186
Haegarda C1 Esterase Inhibitor Brand 15 $765,723
Dupixent Syringe Dupilumab Brand 15 $54,143

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RUCONEST
$17,470 — —
Orladeyo
$5,000 22 —
TAKHZYRO
$4,573 21 —
DUPIXENT
$594 15 —
FASENRA
$353 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

847 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record